Our purpose was to evaluate frequency and severity of bone mineral decrements and frequency of osteonecrosis in survivors of pediatric allogeneic bone marrow transplantation (alloBMT). We retrospectively reviewed demographic information, treatment, magnetic resonance (MR) imaging studies (hips and knees), and bone mineral density (BMD) studies of 48 patients as measured by quantitative computed tomography (QCT). In all, 24 patients were male; 37 were Caucasian. Median age at alloBMT was 10.3 years (1.6-20.4 years). Of the 48 patients, 43 underwent QCT. Median time between alloBMT and imaging was 5.1 years (1.0-10.2 years). Median BMD Z-score was À0.89 (À4.06 to 3.05). BMD Z-score tended to be associated with female sex (P ¼ 0.0559) but not with age at BMT, race, primary diagnosis, time from alloBMT, T-cell depletion of graft, total-body irradiation, or acute/chronic graft-versus-host disease (GVHD). MR showed osteonecrosis in 19 of 43 (44%). We found no associations between osteonecrosis and sex, race, diagnosis, age at BMT, history of GVHD, time from BMT, or T-cell depletion. Seven patients (15%) had MR changes of osteonecrosis and BMD Z-scores of less than -1 s.d. We conclude that pediatric alloBMT survivors have decreased BMD and are at risk of osteonecrosis. They should be monitored to assure early intervention that may ameliorate adverse outcomes.
Summary:
Our purpose was to evaluate frequency and severity of bone mineral decrements and frequency of osteonecrosis in survivors of pediatric allogeneic bone marrow transplantation (alloBMT). We retrospectively reviewed demographic information, treatment, magnetic resonance (MR) imaging studies (hips and knees), and bone mineral density (BMD) studies of 48 patients as measured by quantitative computed tomography (QCT). In all, 24 patients were male; 37 were Caucasian. Median age at alloBMT was 10.3 years (1.6-20.4 years). Of the 48 patients, 43 underwent QCT. Median time between alloBMT and imaging was 5.1 years (1.0-10.2 years). Median BMD Z-score was À0.89 (À4.06 to 3.05). BMD Z-score tended to be associated with female sex (P ¼ 0.0559) but not with age at BMT, race, primary diagnosis, time from alloBMT, T-cell depletion of graft, total-body irradiation, or acute/chronic graft-versus-host disease (GVHD). MR showed osteonecrosis in 19 of 43 (44%). We found no associations between osteonecrosis and sex, race, diagnosis, age at BMT, history of GVHD, time from BMT, or T-cell depletion. Seven patients (15%) had MR changes of osteonecrosis and BMD Z-scores of less than -1 s.d. We conclude that pediatric alloBMT survivors have decreased BMD and are at risk of osteonecrosis. They should be monitored to assure early intervention that may ameliorate adverse outcomes. Owing to the growing success of pediatric alloBMT, an increasing number of longterm survivors are at risk of disease-and therapy-induced adverse late effects, including diminished bone mineral density (BMD) and osteonecrosis. Limited guidelines are available to direct management of survivors of pediatric alloBMT, [1] [2] [3] of which few address potential skeletal complications. 4 To assess the frequency and severity of bone mineral deficits and of osteonecrosis in survivors of childhood alloBMT, we retrospectively reviewed the records of routine annual follow-up evaluations of survivors of pediatric alloBMT treated at a single pediatric transplant center.
Patients and methods
All patients who had follow-up evaluations for alloBMT between March 1, 2001 and November 8, 2001 , and who underwent BMD assessment, and/or magnetic resonance (MR) of the hips and/or knees were eligible for inclusion. Routine evaluation of BMD screening for osteonecrosis using MR was initiated in March 2001. The reported patient cohort comprises a consecutive group of patients who returned for their annual post-BMT evaluation for whom these studies were part of routine evaluation. Information abstracted from medical records review included demographic information, the date and type of primary diagnosis, the alloBMT conditioning regimen (including use of total body irradiation), T-cell depletion of the graft, donor type, date of transplantation, and history of acute or chronic graft-versus-host disease (GVHD). We also retrospectively reviewed all quantitative computed tomography (QCT) and MR imaging studies performed during the annual evaluation of those patients. This study was approved by the St Jude Children's Research Hospital Institutional Review Board (IRB); informed consent was waived for this retrospective study.
Transplantation
All patients underwent alloBMT on IRB-approved protocols. In all, 26 patients received bone marrow from HLA-matched siblings, 25 from matched unrelated donors (matched at five or six HLA loci), and eight from mismatched family members. All patients who had hematologic malignancies (n ¼ 50) were conditioned with cytarabine (3 g/m 2 /dose, six doses) and cyclophosphamide (45 mg/kg/dose, two doses), with mesna uroprotection (45 mg/kg divided into five doses) and received total-body irradiation (TBI) in eight fractions over 4 days in doses of 150 or 175 cGy per fraction. Recipients of matched sibling grafts received 12 Gy and recipients of unrelated or mismatched family member grafts received 14 Gy. Patients with nonmalignant diseases (n ¼ 9) received a preparatory regimen of busulfan (1 mg/kg/dose, 16 doses) and cyclophosphamide (50 mg/kg/dose, four doses) with mesna uroprotection (50 mg/kg, administered as described above).
Recipients of unrelated donor or mismatched family member grafts received antithymocyte globulin to enhance immunosuppression. Marrow from mismatched family members and from unrelated donors was depleted of T lymphocytes by a factor of approximately 1.5 logs using anti-T-cell monoclonal antibodies CD6 and CD8 plus rabbit complement. 5 All recipients began receiving cyclosporin A 2 days before transplantation, at a dosage adjusted to maintain plasma levels of 200-350 ng/ml. Patients given matched sibling marrow received additional GVHD prophylaxis with pentoxifylline or methotrexate (15 mg/m 2 at day þ 1 followed by 10 mg/m 2 at days þ 3, þ 6, and þ 11).
Acute and chronic GVHD were graded according to standard criteria. 6 Patients with mild/moderate GVHD (grade 1 or 2) were treated with methylprednisolone (1-2 mg/kg daily). If GVHD remained at grade 2 for more than 7 days or progressed, the steroid dosage was increased to 5-10 mg/kg daily.
QCT technique
Vertebral trabecular BMD was determined by QCT imaging using a Siemens Somatom-Plus spiral CT scanner (Siemens, Iselin, NY, USA) and Mindwaves QCT Calibration Phantoms and software (Mindwaves Software, Inc., South San Francisco, CA, USA). Bone mineral content was determined through direct axial images of the centers of the bodies of the first and second lumbar vertebrae (L 1 and L 2 , respectively), as determined from a sagittal or coronal scout image as described previously. [6] [7] [8] [9] If either or both bodies showed evidence of fracture or deformity, the affected vertebral bodies were excluded from analysis and an alternate vertebral body between T 11 and L 4 was chosen. BMD was calculated as the mean mg/cm 3 value of the two vertebral bodies.
MR technique
We performed coronal noncontrast T 1 -weighted and short tau inversion recovery imaging of the hips and knees and sagittal FLASH 2-D imaging of the articular surfaces, using a Siemens 1.5 T. Symphony or Vision MR unit (Siemens, Inc., Erlangen, Germany).
Hip and knee radiographs
We no longer routinely perform radiographic evaluation of the hips or knees for assessment of osteonecrosis until such time as orthopedic surgery is contemplated. Thus, from radiographic reports, we captured whether or not patients with MR findings of osteonecrosis underwent radiographic evaluation during the study period and whether or not the radiographs identified the presence of osteonecrosis.
Definitions
The Z-score (number of s.d.'s from the mean for age-and gender-matched control subjects) was used as an end point to allow analysis of the results obtained. BMD values with a Z-score above -1 were considered to be normal. We considered osteopenia as a Z-score between -1 and -2 s.d. and osteoporosis as a Z-score more than 2 s.d. below the mean (as modified from the World Health Organization and National Osteoporosis Foundation criterion for osteopenia). [10] [11] [12] At our institution, we initiate nutritional counseling and suggest calcium and vitamin D supplementation for all patients with a BMD Z-score below -1 s.d.; all patients with a BMD Z-score below -2 s.d. are also referred for endocrinologic consultation for more rigorous evaluation of risk factors that may contribute to BMD deficits. Patients who have undergone BMT are evaluated annually in the Endocrine Clinic.
Statistical analysis
We used univariate analysis and logistic regression to assess if the following factors: age at BMT, age at BMT by group (o10 year vs 410 years), time from completion of therapy, gender, race (black vs white vs others), diagnosis (malignant vs nonmalignant), T-cell depletion (yes vs no), TBI (yes vs no), BMT type (matched sibling vs matched unrelated donor vs mismatched family donor), acute GVHD (grade 2-4 vs others), chronic GVHD (yes vs no), hypothyroidism (yes vs no), hypogonadism (yes vs no), adrenal insufficiency (yes vs no), and growth hormone deficiency (yes vs no) were associated with osteopenia/osteoporosis. The generalized linear model (GLM) was used to further investigate if the following factors were correlated with QCT Z-scores, while ignoring the definition of osteopenia and osteoporosis: age at BMT, age at BMT by group (o10 year vs 410 years), time from completion of therapy, gender, race (black vs white vs others), diagnosis (malignant vs nonmalignant), T-cell depletion (yes vs no), TBI (yes vs no), BMT type (matched sibling vs matched unrelated donor vs mismatched family donor), acute GVHD (grade 2-4 vs others), chronic GVHD (yes vs no), hypothyroidism (yes vs no), hypogonadism (yes vs no), adrenal insufficiency (yes vs no), growth hormone deficiency (yes vs no). Univariate analysis was performed.
Osteonecrosis was defined by characteristic findings on MR imaging of either knees or hips. [13] [14] [15] [16] [17] [18] [19] Patients who did not undergo MR imaging were excluded from the analysis of osteonecrosis. Logistic regression was used to assess the association between osteonecrosis and age at BMT, gender, race (black vs white vs others), diagnosis (malignant vs nonmalignant disease), time from completion of therapy, T-cell depletion (yes vs no), TBI (yes vs no), acute GVHD (grade 2-4 vs others), and chronic GvHD (yes vs no).
All statistical analyses used SAS release 8.1 (SAS Institute, Cary, NC, USA).
Results
Between March 1, 2001 and November 8, 2001 , 65 survivors of alloBMT returned for their yearly anniversary evaluation. In all, 55 patients (77%) underwent QCT and/ or MR studies. Two patients had undergone two bone marrow transplantations and were excluded from this study. Thus, the study cohort comprises 48 patients. Table 1 lists selected characteristics of the 48 cases. Of these, 24 (50%) patients were male, and 37 (77%) were Caucasian. The median age was 10.3 years (range, 1.6-20.4 years) at the time of alloBMT and 15.8 years (range, 4.4-27.2 years) at the time of the follow-up study. The median time elapsed between alloBMT and QCT was 5.1 years (range, 1.0-10.2 years). The most common primary diagnosis was acute myeloid leukemia (AML) (12 patients; 25%); the most common type of donor was a matched sibling (23 patients; 48%). A total of 33 patients (69% studied of the cohort) had endocrinopathies: 28 (58%) hypothyroidism, 15 (31%) hypogonadism, and four (8%) with hypocortisolism, four (8%) with precocious puberty, and four (8%) with growth hormone deficiency. All patients with an endocrinopathy were receiving hormone replacement at the time of BMD determination. 
Bone mineral density
QCT studies were recorded for 43 patients (Table 1) . The median time between BMT and measurement of BMD was 5.1 years (range, 1.0-10.2 years). The QCT Z-scores (n ¼ 43) showed that approximately 21% of the study population has osteoporosis (Z-score less than À2); 26% of patients had osteopenia with BMD Z-scores between À1 and À2 s.d. Logistic regression analysis showed no significant association between osteopenia/osteoporosis (a QCT Z-score oÀ1) and age at the time of BMT, race, sex, time elapsed since BMT, T-cell depletion, TBI, acute/chronic GVHD, and diagnosis. However, when the GLM was used to test the association between these variables and the Z-scores without reference to the threshold defining osteopenia/ osteoporosis, sex and hypogonadism had P-values of 0.0559 and 0.0637, respectively, suggesting trends toward significances with BMD below the mean for age-and gender-matched controls. Male patients had higher QCT Z-scores than did females (P ¼ 0.0559). The estimated mean Z-score (s.d.) was À0.33 (1.42) for male and À1.18 (1.42) for female patients, respectively.
Patients with hypogonadism had lower QCT Z-scores than patients without hypogonadism (P ¼ 0.0637). The estimated mean Z-score (s.d.) for patients with hypogonadism and without hypogonadism were À1.39 (1.32) and À0.47 (1.46), respectively. Age at time of BMT, type of BMT, time from BMT, type of BMT, T-cell depletion, TBI, acute/chronic GVHD, race, and diagnosis did not correlate with BMD Z-score. We found no correlation with endocrinopathy other than hypogonadism.
MR imaging evidence of osteonecrosis
Of the 48 evaluable patients, 43 had undergone MR imaging of the hips and and/or knees; 19 had evidence of osteonecrosis. In all, 12 (63%) were female and seven (37%) were male. Female sex was significantly associated with osteonecrosis. No associations were observed between osteonecrosis and sex, race, diagnosis, age at BMT, history of acute/chronic GVHD, time from BMT, or T-cell depletion. Of patients with positive MR findings, eight (42%) were clinically significant (one of whom had undergone hip arthroplasty and one underwent core decompression of the hip). Two patients also had involvement of the ankles and one patient had involvement of the elbows. Of the 19 patients with MR evidence of osteoncrosis, 12 underwent radiographic evaluation of the hips (two positive) and two of the knees (one positive).
Seven patients (15%) had both MR changes suggestive of osteonecrosis involving the hips (n ¼ 2), knees (n ¼ 4) or both (n ¼ 1), and BMD Z-scores less than À1 s.d. The BMD Z-scores obtained by QCT for these patients ranged from À1.35 to À3.30.
Discussion
As the surviving cohort of pediatric patients treated with alloBMT grows, skeletal complications related to disease and treatment are becoming progressively more important. Previous studies of childhood cancer patients indicating bone mineral deficits have prompted screening of this at risk population in an effort to reduce the morbidity and mortality associated with osteonecrosis and early-onset osteoporosis. Most of our patients undergo QCT assessment of BMD and MR of the hips and knees as part of their annual post-BMT examination. However, routine imaging examination is costly in terms of resource utilization, patient and staff time, and financial resources, and it exposes patients to small amounts of ionizing radiation. We therefore sought to estimate the frequency of osteopenia/osteoporosis and osteonecrosis in survivors of alloBMT returning for long-term follow-up.
Bone mineral decrements
Bone mineral loss as an adverse effect of childhood oncotherapy is the subject of intense interest. The development of this sequela is complex and multifactorial. [1] [2] [3] [4] [20] [21] [22] Malignant disease, its therapy, altered nutrition during therapy, physical inactivity, and GVHD and its therapy compound any innate deficits that may be present at the time of alloBMT. 4 Osteoporosis has been reported following allogeneic BMT for a variety of diagnoses in adults. 4, [23] [24] [25] However, studies of osteoporosis in children following autologous or allogeneic BMT are limited.
1,4,25
Bhatia et al 25 reported that the DXA-determined BMD of 10 pediatric patients aged 3 to18 years, most of whom underwent allogeneic BMT for AML, was significantly decreased (median Z-score of À0.5) and lower than that of 13 adults in the same study (median Z-score of 0.0, P ¼ 0.03). Our study corroborates the finding of BMD deficits in a larger cohort of pediatric alloBMT survivors. We found an even greater BMD deficit (median Z-score, À0.88) than previously reported, possibly in part be due to a difference in technologic assessment (ie DXA vs QCT). Our longer median follow-up period of nearly 5 years (as opposed to the 2 years median follow-up in Bhatia's study) permitted more time for any natural recovery of BMD, were it to occur. The presence of osteopenia (26%) or osteoporosis (21%) in 47% of our cohort suggests that survivors of alloBMT during childhood will carry excess risks of fractures and other skeletal complications as they age.
Several groups have evaluated clinical and treatment factors predictive of BMD deficits. Glucocorticoid [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] and methotrexate [36] [37] [38] [39] treatment and cranial irradiation [40] [41] [42] have been inconsistently associated with the risk of osteopenia. However, findings of these studies have been limited by the generally small and heterogeneously treated patient cohorts. Among the few studies reporting BMD after BMT, Stern et al 24 at the University of Washington Fred Hutchinson Cancer Research Center found a positive correlation between treatment for chronic GVHD with cyclosporin A and prednisone and BMD deficits, as determined by DXA in six of nine adult patients during 6 months of immunosuppression. Males with greater post transplant complications had greater loss of BMD. 24 As also reported by Bhatia et al, 25 we found no such correlation in our pediatric cohort.
Bone mineral accretion is most active during puberty because of the intimate association between bone mineral accretion and pubertal development. 3, 22, 43 A balance between gonadal, thyroid, adrenal, and growth hormones is necessary for maximum bone mineral accretion and skeletal development. Gonadal failure related to transplant therapy is well known and multifactorial. 1, [44] [45] [46] Primary ovarian failure is expected in adult women who have undergone bone marrow transplantation with less than 10% reportedly regaining ovarian function between 3 and 7 years after total body irradiation. 1, 44, 45 Most children who received total body irradiation when younger than 10 years progress through puberty normally. However, those who were at least 10 years of age at the time of total body irradiation developed primary gonadal failure. 45 In about 75% of men who have received irradiation, elevation of follicle-stimulating hormone persisted even in the presence of normal or recovered luteinizing hormone and normal testosterone.
1 Thus, the trend we found between hypogonadism and bone mineral deficits is not surprising and underscores the need to prospectively monitor alloBMT patients for gonadal function.
Osteonecrosis
Identification of osteonecrosis at an early stage allows intervention that may arrest progression of pain and functional impairment. Previous studies have utilized radiography of the hips to detect osteonecrosis, 23, 47 but current MR imaging technology provides earlier, more sensitive, and specific detection. 13, [15] [16] [17] [18] 48 We perform MR imaging to identify osteonecrosis involving the hips or knees annually or when indicated by clinical symptoms such as chronic joint pain.
Orthopedic management of osteonecrosis is based on symptoms and joint function. In the early stages, patients are treated with nonweight-bearing activities such as swimming to maintain joint function and to control body weight. 14, 49 At more advanced stages, surgical intervention (ie core decompression, arthroplasty, or total joint replacement) may be necessary to ameliorate symptoms and preserve joint function. 14, 49 Using multivariate analysis, investigators at the University of Minnesota identified increasing age at the time of BMT (P ¼ 0.002), acute or chronic GVHD requiring steroid therapy (P ¼ 0.003) as significant and independent risk factors for developing osteonecrosis after allogeneic transplantation in 28 (4%) of 642 consecutive patients ranging in age from 1.5 to 47 years (median, 26 years) at the time of BMT. Symptoms developed a median of 12 months after transplantation, but in 17 cases diagnosis was delayed (range 0.5-24 months). 23 We failed to find a correlation between GVHD and the development of osteonecrosis, possibly because our cohort was relatively small and of younger age than the comparison group reported above. In addition, few of our patients developed either acute or chronic GVHD as reported previously. 50 As we routinely T-cell deplete all unrelated donor and mismatched family member grafts, our incidence of acute and chronic GVHD is low for the entire alloBMT population. 51 Thus, they would have had less exposure to bone-toxic immunosuppressive drugs. Enright et al 23 used standard radiography, technetium99m MDP bone scintigraphy, and MR imaging to identify osteonecrosis of bone in eight of 353 pediatric recipients (2%) of allogeneic transplants aged 0-19 years. They identified GVHD (acute or chronic) and increasing age as significant independent risk factors for the development of osteonecrosis. Patients aged 10-19 years had a risk of AVN 2.4 times that of patients aged less than 10 years. 23 We found a much greater frequency of osteonecrosis in our study than reported in previous studies that utilized radiographs. 23, 47 Half of the patients we examined, most of whom were female, had MR evidence of osteonecrosis. This increased frequency reflects the greater sensitivity of MR imaging. Our post transplant population underwent screening due to an anticipated increased risk of therapy-related osteonecrosis. Nearly half of those identified with osteonecrosis were asymptomatic or had limited symptoms. It is possible that early conservative intervention might ameliorate the more severe latent sequelae seen in the symptomatic patients; this has yet to be proven in asymptomatic patients. Further, the median age of patients in our cohort was about 10 years at the time of alloBMT, which historically should place them at greater risk of osteonecrosis than younger patients. 23 However, we found no association between patient age at the time of alloBMT and the development of osteonecrosis. Interestingly, the frequency of involvement of the knees exceeded that of the hips; a finding that, to our knowledge, has not been reported previously.
Summary
Osteopenia and osteoporosis typically remain asymptomatic until fractures occur. Patients who are at risk should be screened and treated for conditions that adversely affect bone mineralization, such as hypogonadism and hypothyroidism. 20, 21, 24, 25 Prevention of osteoporosis by optimizing behaviors to improve and maintain bone health should be an important aim of education in follow-up clinics.
Therapy for osteopenia/osteoporosis can undermine therapy for osteonecrosis. Approximately, 15% of our studied cohort had evidence of both decreased BMD and osteonecrosis. However, weight-bearing exercise such as walking, gardening, running, team sports, etc, which have been shown to improve BMD, may exacerbate the symptoms and progression of osteonecrosis. For this patient cohort, weight-bearing exercise should be adjusted to the level of tolerance.
Until proven otherwise, diagnosis and management of osteonecrosis should be symptom based and should conform to orthopedic practice. However, we recommend routine screening of BMD for all alloBMT patients. Patients should be advised to evaluate all behaviors adversely affecting bone health. We specifically counsel our patients to avoid smoking, limit intake of caffeine and carbonated beverages, establish a weight-bearing exercise regimen after orthopedic consultation, and assure adequate dietary intake of calcium and vitamin D. Patients should also be treated for other conditions that affect BMD such as hypogonadism and hypothyroidism.
